Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.83 USD | +0.32% | +14.39% | -31.06% |
05-02 | BridgeBio Pharma Shares Decline After Q1 Financial Results | MT |
05-02 | Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q1 Revenue $211.1M | MT |
Evolution of the average Target Price on BridgeBio Pharma, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering BridgeBio Pharma, Inc.
JPMorgan Chase | |
Cantor Fitzgerald | |
Mizuho Securities | |
Citigroup | |
HC Wainwright | |
Raymond James | |
Goldman Sachs | |
Jefferies & Co. | |
Evercore ISI | |
SVB Securities LLC | |
Cowen | |
SVB Financial | |
SVB Leerink | |
UBS | |
BTIG | |
BofA Securities | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- BBIO Stock
- Consensus BridgeBio Pharma, Inc.